Angiotensin Receptor Neprilysin Inhibitors for Hypertension and Proteinuria Management During Atezolizumab/Bevacizumab Treatment for Hepatocellular Carcinoma
ARNI appears to support renal function preservation and proteinuria reduction during Atez/Bev therapy, allowing the continuation of Bev treatment.
Authors
- Ryo Sato (ORCID: https://orcid.org/0000-0002-1340-4739)
- Junji Yokoyama (ORCID: https://orcid.org/0000-0002-1810-7709)
- Takahiro Iwasawa
- Toru Ishikawa (ORCID: https://orcid.org/0000-0002-5470-9694)
- Masahiro Ogawa (ORCID: https://orcid.org/0000-0002-1549-6008)
- Toshifumi Sato
- Yuji Kobayashi
- Terasu Honma
- HIROKI NATSUI
Institutions
- Saiseikai Niigata Daini Hospital (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2025-07-01
- DOI
- https://doi.org/10.21873/cdp.10462
- Citations
- 1
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 1.47